252 related articles for article (PubMed ID: 30450942)
41. Using oral vancomycin prescriptions as a proxy measure for Clostridium difficile infections: a spatial and time series analysis.
Polgreen PM; Yang M; Kuntz JL; Laxminarayan R; Cavanaugh JE
Infect Control Hosp Epidemiol; 2011 Jul; 32(7):723-6. PubMed ID: 21666407
[TBL] [Abstract][Full Text] [Related]
42. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
43. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection.
Sehgal K; Zandvakili I; Tariq R; Pardi DS; Khanna S
Expert Rev Anti Infect Ther; 2022 Apr; 20(4):577-583. PubMed ID: 34693838
[TBL] [Abstract][Full Text] [Related]
44. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
45. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
47. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
48. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
49. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
Na'amnih W; Adler A; Miller-Roll T; Cohen D; Carmeli Y
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1281-1288. PubMed ID: 29627951
[TBL] [Abstract][Full Text] [Related]
51. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
53. Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.
Sun Y; Huskey RL; Tang L; Inaba H; Gaur AH; Ribeiro R; Rubnitz JE; Wolf J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29229640
[TBL] [Abstract][Full Text] [Related]
54. Recurrent
Song JH; Kim YS
Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734
[TBL] [Abstract][Full Text] [Related]
55. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
[TBL] [Abstract][Full Text] [Related]
56. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection.
Bass SN; Lam SW; Bauer SR; Neuner EA
J Pharm Pract; 2015 Apr; 28(2):183-8. PubMed ID: 24375999
[TBL] [Abstract][Full Text] [Related]
57. Oral Vancomycin Prophylaxis for Clostridioides difficile Infection: Cause or Effect?
Hurley JC
Clin Infect Dis; 2021 Nov; 73(9):e2850-e2851. PubMed ID: 32948875
[No Abstract] [Full Text] [Related]
58. Recent developments in the management of recurrent Clostridioides difficile infection.
Mendo-Lopez R; Villafuerte-Gálvez J; White N; Mahoney MV; Kelly CP; Alonso CD
Anaerobe; 2020 Apr; 62():102108. PubMed ID: 31606481
[TBL] [Abstract][Full Text] [Related]
59. [Individualized treatment strategies for Clostridium difficile infections].
Solbach P; Dersch P; Bachmann O
Internist (Berl); 2017 Jul; 58(7):675-681. PubMed ID: 28589214
[TBL] [Abstract][Full Text] [Related]
60. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.
Sirbu BD; Soriano MM; Manzo C; Lum J; Gerding DN; Johnson S
Clin Infect Dis; 2017 Oct; 65(8):1396-1399. PubMed ID: 28591789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
